{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T14:49:32Z","timestamp":1762008572385,"version":"build-2065373602"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"S15","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1186\/s12859-018-2416-7","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T12:47:23Z","timestamp":1543236443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase"],"prefix":"10.1186","volume":"19","author":[{"given":"Chiara","family":"Cimmaruta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Citro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vittoria","family":"Cubellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Hay Mele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"issue":"11.10","key":"2416_CR1","first-page":"11","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43(11.10):11\u201333.","journal-title":"Curr Protoc Bioinformatics"},{"issue":"10","key":"2416_CR2","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/nprot.2015.105","volume":"10","author":"H Yang","year":"2015","unstructured":"Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 2015;10(10):1556\u201366.","journal-title":"Nat Protoc"},{"issue":"7","key":"2416_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/jmedgenet-2012-100918","volume":"49","author":"X Chang","year":"2012","unstructured":"Chang X, Wang K. wANNOVAR: annotating genetic variants for personal genomes via the web. J Med Genet. 2012;49(7):433\u20136.","journal-title":"J Med Genet"},{"issue":"13","key":"2416_CR4","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1093\/nar\/gkg509","volume":"31","author":"PC Ng","year":"2003","unstructured":"Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812\u20134.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"2416_CR5","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1101\/gr.092619.109","volume":"19","author":"S Chun","year":"2009","unstructured":"Chun S, Fay JC. Identification of deleterious mutations within three human genomes. Genome Res. 2009;19(9):1553\u201361.","journal-title":"Genome Res"},{"issue":"17","key":"2416_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr407","volume":"39","author":"B Reva","year":"2011","unstructured":"Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 2011;39(17):e118.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2416_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/humu.22225","volume":"34","author":"HA Shihab","year":"2013","unstructured":"Shihab HA, Gough J, Cooper DN, Stenson PD, Barker GL, Edwards KJ, Day IN, Gaunt TR. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat. 2013;34(1):57\u201365.","journal-title":"Hum Mutat"},{"issue":"10","key":"2416_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046688","volume":"7","author":"Y Choi","year":"2012","unstructured":"Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7(10):e46688.","journal-title":"PLoS One"},{"issue":"Suppl 3","key":"2416_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/1471-2164-14-S3-S3","volume":"14","author":"H Carter","year":"2013","unstructured":"Carter H, Douville C, Stenson PD, Cooper DN, Karchin R. Identifying Mendelian disease genes with the variant effect scoring tool. BMC Genomics. 2013;14(Suppl 3):S3.","journal-title":"BMC Genomics"},{"issue":"8","key":"2416_CR10","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1093\/hmg\/ddu733","volume":"24","author":"C Dong","year":"2015","unstructured":"Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, Liu X. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet. 2015;24(8):2125\u201337.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"2416_CR11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/ng.3703","volume":"48","author":"KA Jagadeesh","year":"2016","unstructured":"Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN, Bernstein JA, Bejerano G. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat Genet. 2016;48(12):1581\u20136.","journal-title":"Nat Genet"},{"issue":"4","key":"2416_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248\u20139.","journal-title":"Nat Methods"},{"issue":"8","key":"2416_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nmeth0810-575","volume":"7","author":"JM Schwarz","year":"2010","unstructured":"Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7(8):575\u20136.","journal-title":"Nat Methods"},{"issue":"3","key":"2416_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"M Kircher","year":"2014","unstructured":"Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310\u20135.","journal-title":"Nat Genet"},{"issue":"5","key":"2416_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/bioinformatics\/btu703","volume":"31","author":"D Quang","year":"2015","unstructured":"Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. Bioinformatics. 2015;31(5):761\u20133.","journal-title":"Bioinformatics"},{"issue":"10","key":"2416_CR16","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/bioinformatics\/btv009","volume":"31","author":"HA Shihab","year":"2015","unstructured":"Shihab HA, Rogers MF, Gough J, Mort M, Cooper DN, Day IN, Gaunt TR, Campbell C. An integrative approach to predicting the functional effects of non-coding and coding sequence variation. Bioinformatics. 2015;31(10):1536\u201343.","journal-title":"Bioinformatics"},{"key":"2416_CR17","doi-asserted-by":"publisher","first-page":"10576","DOI":"10.1038\/srep10576","volume":"5","author":"Q Lu","year":"2015","unstructured":"Lu Q, Hu Y, Sun J, Cheng Y, Cheung KH, Zhao H. A statistical framework to predict functional non-coding regions in the human genome through integrated analysis of annotation data. Sci Rep. 2015;5:10576.","journal-title":"Sci Rep"},{"issue":"4","key":"2416_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nmeth0410-250","volume":"7","author":"GM Cooper","year":"2010","unstructured":"Cooper GM, Goode DL, Ng SB, Sidow A, Bamshad MJ, Shendure J, Nickerson DA. Single-nucleotide evolutionary constraint scores highlight disease-causing mutations. Nat Methods. 2010;7(4):250\u20131.","journal-title":"Nat Methods"},{"issue":"12","key":"2416_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1001025","volume":"6","author":"EV Davydov","year":"2010","unstructured":"Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol. 2010;6(12):e1001025.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"2416_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1101\/gr.097857.109","volume":"20","author":"KS Pollard","year":"2010","unstructured":"Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 2010;20(1):110\u201321.","journal-title":"Genome Res"},{"issue":"8","key":"2416_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1101\/gr.3715005","volume":"15","author":"A Siepel","year":"2005","unstructured":"Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, Clawson H, Spieth J, Hillier LW, Richards S, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005;15(8):1034\u201350.","journal-title":"Genome Res"},{"issue":"12","key":"2416_CR22","doi-asserted-by":"publisher","first-page":"i54","DOI":"10.1093\/bioinformatics\/btp190","volume":"25","author":"M Garber","year":"2009","unstructured":"Garber M, Guttman M, Clamp M, Zody MC, Friedman N, Xie X. Identifying novel constrained elements by exploiting biased substitution patterns. Bioinformatics. 2009;25(12):i54\u201362.","journal-title":"Bioinformatics"},{"issue":"2","key":"2416_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","volume":"337","author":"SC Garman","year":"2004","unstructured":"Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol. 2004;337(2):319\u201335.","journal-title":"J Mol Biol"},{"issue":"22","key":"2416_CR24","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1021\/bi9002265","volume":"48","author":"RL Lieberman","year":"2009","unstructured":"Lieberman RL, D\u2019Aquino JA, Ringe D, Petsko GA. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry. 2009;48(22):4816\u201327.","journal-title":"Biochemistry"},{"issue":"6","key":"2416_CR25","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","volume":"285","author":"AI Guce","year":"2010","unstructured":"Guce AI, Clark NE, Salgado EN, Ivanen DR, Kulminskaya AA, Brumer H 3rd, Garman SC. Catalytic mechanism of human alpha-galactosidase. J Biol Chem. 2010;285(6):3625\u201332.","journal-title":"J Biol Chem"},{"key":"2416_CR26","unstructured":"Mehta A, Hughes DA: Fabry disease. 1993."},{"key":"2416_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2416_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1517\/17530059.2013.846322","volume":"7","author":"AS Thomas","year":"2013","unstructured":"Thomas AS, Mehta AB. Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature? Expert Opin Med Diagn. 2013;7(6):589\u201399.","journal-title":"Expert Opin Med Diagn"},{"issue":"12","key":"2416_CR29","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3390\/ijms17122010","volume":"17","author":"Valentina Citro","year":"2016","unstructured":"Citro V, Cammisa M, Liguori L, Cimmaruta C, Lukas J, Cubellis MV, Andreotti G. The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations. Int J Mol Sci. 2016;17(12).","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"2416_CR30","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2416_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C Tondel","year":"2013","unstructured":"Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24(1):137\u201348.","journal-title":"J Am Soc Nephrol"},{"key":"2416_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2416_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","volume":"109","author":"R Giugliani","year":"2013","unstructured":"Giugliani R, Waldek S, Germain DP, Nicholls K, Bichet DG, Simosky JK, Bragat AC, Castelli JP, Benjamin ER, Boudes PF. A phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol Genet Metab. 2013;109(1):86\u201392.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2416_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, et al. Treatment of Fabry's disease with the pharmacologic chaperone Migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"issue":"4","key":"2416_CR35","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430\u20138.","journal-title":"Genet Med"},{"issue":"12","key":"2416_CR36","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","volume":"18","author":"AI Guce","year":"2011","unstructured":"Guce AI, Clark NE, Rogich JJ, Garman SC. The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem Biol. 2011;18(12):1521\u20136.","journal-title":"Chem Biol"},{"key":"2416_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/bs.apcsb.2015.10.001","volume":"102","author":"SA Haneef","year":"2016","unstructured":"Haneef SA, Doss CG. Personalized Pharmacoperones for Lysosomal storage disorder: approach for next-generation treatment. Adv Protein Chem Struct Biol. 2016;102:225\u201365.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"447","key":"2416_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/08035320510028157","volume":"94","author":"TM Cox","year":"2005","unstructured":"Cox TM. Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr Suppl. 2005;94(447):69\u201375 discussion 57.","journal-title":"Acta Paediatr Suppl"},{"issue":"11","key":"2416_CR39","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","volume":"269","author":"FM Platt","year":"1994","unstructured":"Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994;269(11):8362\u20135.","journal-title":"J Biol Chem"},{"issue":"5","key":"2416_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/00042560-199510050-00008","volume":"10","author":"M Tierney","year":"1995","unstructured":"Tierney M, Pottage J, Kessler H, Fischl M, Richman D, Merigan T, Powderly W, Smith S, Karim A, Sherman J, et al. The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(5):549\u201353.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"2416_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13023-015-0273-2","volume":"10","author":"B Hay Mele","year":"2015","unstructured":"Hay Mele B, Citro V, Andreotti G, Cubellis MV. Drug repositioning can accelerate discovery of pharmacological chaperones. Orphanet J Rare Dis. 2015;10:55.","journal-title":"Orphanet J Rare Dis"},{"key":"2416_CR42","unstructured":"Whybra C, Bahner F, Baron K: Measurement of disease severity and progression in Fabry disease. 2006."},{"issue":"3","key":"2416_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/jhg.2010.5","volume":"55","author":"S Saito","year":"2010","unstructured":"Saito S, Ohno K, Sese J, Sugawara K, Sakuraba H. Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information. J Hum Genet. 2010;55(3):175\u20138.","journal-title":"J Hum Genet"},{"issue":"6","key":"2416_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/jhg.2011.31","volume":"56","author":"S Saito","year":"2011","unstructured":"Saito S, Ohno K, Sakuraba H. Fabry-database.org: database of the clinical phenotypes, genotypes and mutant alpha-galactosidase a structures in Fabry disease. J Hum Genet. 2011;56(6):467\u20138.","journal-title":"J Hum Genet"},{"issue":"8","key":"2416_CR45","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/humu.21530","volume":"32","author":"X Wu","year":"2011","unstructured":"Wu X, Katz E, Della Valle MC, Mascioli K, Flanagan JJ, Castelli JP, Schiffmann R, Boudes P, Lockhart DJ, Valenzano KJ, et al. A pharmacogenetic approach to identify mutant forms of alpha-galactosidase a that respond to a pharmacological chaperone for Fabry disease. Hum Mutat. 2011;32(8):965\u201377.","journal-title":"Hum Mutat"},{"key":"2416_CR46","doi-asserted-by":"crossref","unstructured":"Lukas J, Knospe AM, Seemann S, Citro V, Cubellis MV, Rolfs A. In vitro enzyme measurement to test pharmacological chaperone responsiveness in Fabry and Pompe disease. J Vis Exp. 2017;130.","DOI":"10.3791\/56550"},{"key":"2416_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-1172-5-36","volume":"5","author":"G Andreotti","year":"2010","unstructured":"Andreotti G, Guarracino MR, Cammisa M, Correra A, Cubellis MV. Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study. Orphanet J Rare Dis. 2010;5:36.","journal-title":"Orphanet J Rare Dis"},{"key":"2416_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1750-1172-8-111","volume":"8","author":"M Cammisa","year":"2013","unstructured":"Cammisa M, Correra A, Andreotti G, Cubellis MV. Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones. Orphanet J Rare Dis. 2013;8:111.","journal-title":"Orphanet J Rare Dis"},{"issue":"D1","key":"2416_CR49","doi-asserted-by":"publisher","first-page":"D754","DOI":"10.1093\/nar\/gkx1098","volume":"46","author":"DR Zerbino","year":"2018","unstructured":"Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, Billis K, Cummins C, Gall A, Giron CG, et al. Ensembl 2018. Nucleic Acids Res. 2018;46(D1):D754\u201361.","journal-title":"Nucleic Acids Res"},{"key":"2416_CR50","unstructured":"Team RC: R: a language and environment for statistical computing. 2013."},{"issue":"1","key":"2416_CR51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44\u201354.","journal-title":"Clin Genet"},{"issue":"D1","key":"2416_CR52","doi-asserted-by":"publisher","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","volume":"44","author":"MJ Landrum","year":"2016","unstructured":"Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Hoover J, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44(D1):D862\u20138.","journal-title":"Nucleic Acids Res"},{"key":"2416_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13040-017-0155-3","volume":"10","author":"D Chicco","year":"2017","unstructured":"Chicco D. Ten quick tips for machine learning in computational biology. BioData Min. 2017;10:35.","journal-title":"BioData Min"},{"issue":"2","key":"2416_CR54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1006\/abbi.2000.1743","volume":"377","author":"S Ishii","year":"2000","unstructured":"Ishii S, Suzuki Y, Fan JQ. Role of Ser-65 in the activity of alpha-galactosidase a: characterization of a point mutation (S65T) detected in a patient with Fabry disease. Arch Biochem Biophys. 2000;377(2):228\u201333.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"2416_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2416_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3858\/emm.2009.41.1.001","volume":"41","author":"JY Park","year":"2009","unstructured":"Park JY, Kim GH, Kim SS, Ko JM, Lee JJ, Yoo HW. Effects of a chemical chaperone on genetic mutations in alpha-galactosidase a in Korean patients with Fabry disease. Exp Mol Med. 2009;41(1):1\u20137.","journal-title":"Exp Mol Med"},{"issue":"2","key":"2416_CR57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bbadis.2009.11.003","volume":"1802","author":"C Filoni","year":"2010","unstructured":"Filoni C, Caciotti A, Carraresi L, Cavicchi C, Parini R, Antuzzi D, Zampetti A, Feriozzi S, Poisetti P, Garman SC, et al. Functional studies of new GLA gene mutations leading to conformational Fabry disease. Biochim Biophys Acta. 2010;1802(2):247\u201352.","journal-title":"Biochim Biophys Acta"},{"key":"2416_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1750-1172-6-66","volume":"6","author":"G Andreotti","year":"2011","unstructured":"Andreotti G, Citro V, De Crescenzo A, Orlando P, Cammisa M, Correra A, Cubellis MV. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests. Orphanet J Rare Dis. 2011;6:66.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2416_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"J Lukas","year":"2013","unstructured":"Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, Lackner KJ, Meyer W, Wree P, Saviouk V, et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet. 2013;9(8):e1003632.","journal-title":"PLoS Genet"},{"issue":"3","key":"2416_CR60","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.bbagen.2013.12.018","volume":"1840","author":"G Andreotti","year":"2014","unstructured":"Andreotti G, Citro V, Correra A, Cubellis MV. A thermodynamic assay to test pharmacological chaperones for Fabry disease. Biochim Biophys Acta. 2014;1840(3):1214\u201324.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"2416_CR61","doi-asserted-by":"publisher","first-page":"e0165463","DOI":"10.1371\/journal.pone.0165463","volume":"11","author":"V Citro","year":"2016","unstructured":"Citro V, Pena-Garcia J, den-Haan H, Perez-Sanchez H, Del Prete R, Liguori L, Cimmaruta C, Lukas J, Cubellis MV, Andreotti G. Identification of an allosteric binding site on human Lysosomal alpha-Galactosidase opens the way to new pharmacological chaperones for Fabry disease. PLoS One. 2016;11(10):e0165463.","journal-title":"PLoS One"},{"issue":"1","key":"2416_CR62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/humu.22910","volume":"37","author":"J Lukas","year":"2016","unstructured":"Lukas J, Scalia S, Eichler S, Pockrandt AM, Dehn N, Cozma C, Giese AK, Rolfs A. Functional and clinical consequences of novel alpha-Galactosidase a mutations in Fabry disease. Hum Mutat. 2016;37(1):43\u201351.","journal-title":"Hum Mutat"},{"issue":"3","key":"2416_CR63","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/humu.22932","volume":"37","author":"X Liu","year":"2016","unstructured":"Liu X, Wu C, Li C, Boerwinkle E. dbNSFP v3.0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum Mutat. 2016;37(3):235\u201341.","journal-title":"Hum Mutat"},{"issue":"7616","key":"2416_CR64","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285\u201391.","journal-title":"Nature"},{"issue":"7422","key":"2416_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nature11632","volume":"491","author":"GR Abecasis","year":"2012","unstructured":"Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56\u201365.","journal-title":"Nature"},{"issue":"6","key":"2416_CR66","first-page":"1186","volume":"53","author":"CM Eng","year":"1993","unstructured":"Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the alpha-galactosidase a gene that cause Fabry disease. Am J Hum Genet. 1993;53(6):1186\u201397.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2416_CR67","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13059-017-1353-5","volume":"18","author":"R Ghosh","year":"2017","unstructured":"Ghosh R, Oak N, Plon SE. Evaluation of in silico algorithms for use with ACMG\/AMP clinical variant interpretation guidelines. Genome Biol. 2017;18(1):225.","journal-title":"Genome Biol"},{"key":"2416_CR68","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.biochi.2015.03.018","volume":"113","author":"MV Cubellis","year":"2015","unstructured":"Cubellis MV, Baaden M, Andreotti G. Taming molecular flexibility to tackle rare diseases. Biochimie. 2015;113:54\u20138.","journal-title":"Biochimie"},{"issue":"W1","key":"2416_CR69","doi-asserted-by":"publisher","first-page":"W229","DOI":"10.1093\/nar\/gkx439","volume":"45","author":"AP Pandurangan","year":"2017","unstructured":"Pandurangan AP, Ochoa-Montano B, Ascher DB, Blundell TL. SDM: a server for predicting effects of mutations on protein stability. Nucleic Acids Res. 2017;45(W1):W229\u201335.","journal-title":"Nucleic Acids Res"},{"key":"2416_CR70","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1471-2105-12-151","volume":"12","author":"Y Dehouck","year":"2011","unstructured":"Dehouck Y, Kwasigroch JM, Gilis D, Rooman M. PoPMuSiC 2.1: a web server for the estimation of protein stability changes upon mutation and sequence optimality. BMC Bioinform. 2011;12:151.","journal-title":"BMC Bioinform"},{"issue":"3","key":"2416_CR71","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/bioinformatics\/btt691","volume":"30","author":"DE Pires","year":"2014","unstructured":"Pires DE, Ascher DB, Blundell TL. mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics. 2014;30(3):335\u201342.","journal-title":"Bioinformatics"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-018-2416-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12859-018-2416-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-018-2416-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T22:26:15Z","timestamp":1662503175000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-018-2416-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":71,"journal-issue":{"issue":"S15","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["2416"],"URL":"https:\/\/doi.org\/10.1186\/s12859-018-2416-7","relation":{},"ISSN":["1471-2105"],"issn-type":[{"type":"electronic","value":"1471-2105"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"30 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"433"}}